Ultragenyx posts Q3 loss, announces expense cuts and reaffirms 2026 revenue guidance
Ultragenyx Pharmaceutical reported third‑quarter 2026 revenue of $173 million and a net loss of $118 million, or $1.16 per share. The company received FDA approvals for its gene therapies GENGLYCOS and FAYUVI and sold the associated priority‑review vouchers for a combined $413 million. It announced a roughly 20% headcount reduction and said the cuts will help achieve profitability in 2027 while reaffirming its full‑year 2026 revenue outlook of $730 million‑$760 million.
Why it matters
The company expects the expense reductions and PRV proceeds to drive a transition to GAAP profitability in 2027. Reaffirmed revenue guidance signals that the new product launches will not be needed to meet the 2026 target, reducing upside risk for investors.
Key facts
- 1Total revenue in the third quarter 2026 was $173 million. sec.gov
- 2Net loss for the quarter was $118 million, or $1.16 per share basic and diluted. sec.gov
- 3The FDA approved two gene‑therapy BLAs, GENGLYCOS and FAYUVI, in the quarter. sec.gov
- 4Two priority‑review vouchers were sold for a combined price of $413 million, with net proceeds expected to be about $350 million. sec.gov
- 5Ultragenyx is reducing headcount by approximately 20%, to a workforce of roughly 1,000 employees. sec.gov
- 6The company reaffirmed its full‑year 2026 revenue guidance of $730 million‑$760 million, excluding revenue from the new launches. sec.gov
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.